海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.
- Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2018-04-20
Authorised
- Studio internazionale per il trattamento della leucemia linfoblastica acuta Philadelphia positiva
- Leucemia Linfoblastica Acuta Ph + MedDRA version: 20.1 Level: LLT Classification code 10000844 Term: Acute lymphoblastic leukaemia System Organ Class: 100000004864 MedDRA version: 20.1 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, Chile, European Union, Hong Kong, Israel, Italy, Switzerland, United States
- 2018-02-12
Authorised
- This is a study to evaluate the safety and effectiveness of Tolvaptan in adults with chronic kidney disease
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) MedDRA version: 18.1 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominant System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2014-07-31
Authorised
- This is a study to evaluate the long term safety of Tolvaptan in adults with chronic kidney disease.
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) MedDRA version: 20.0 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominant System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
- 2014-09-30
Authorised
- An Early Phase Study of DCR-PH1 in Patients with an Inherited Disorder Resulting in Overproduction of Oxalate
- Primary Hyperoxaluria Type 1 MedDRA version: 18.0 Level: PT Classification code 10020703 Term: Hyperoxaluria System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- France, Germany, Israel, Netherlands, United Kingdom, United States
- 2015-10-06
Authorised
- A Phase 2 clinical study to evaluate the safety and efficacy of the study medication CO-1686 in subjects with Previously Treated EGFR Non-Small Cell Lung Cancer
- Previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor MedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Germany, Hong Kong, Korea, Republic of, Netherlands, Spain, Switzerland, Taiwan, United Kingdom, United States
- 2014-04-09
Authorised
- A Study of Ramucirumab plus Docetaxel in Participants with Urothelial Cancer
- Locally advanced or unresectable or metastatic urothelial carcinoma who have had disease progression on or after one prior first-line platinum-based chemotherapy. br>MedDRA version: 18.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Democratic People's Republic of, Netherlands, Poland, Romania, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States
- 2015-03-11
Authorised
- Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC
- First-line treatment of metastatic NSCLC MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2017-11-02
Authorised
- Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancer
- Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-10-25
Authorised
- Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancer
- Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-10-19
